New drug cocktail aims to boost bile duct cancer treatment

NCT ID NCT07107750

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called emavusertib added to standard chemotherapy and immunotherapy for people with untreated advanced bile duct cancer. The goal is to see if the combination is safe and to find the best dose. About 48 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emavusertib (CA-4948) combined with cisplatin, gemcitabine, and durvalumab
What this could lead to: If it works, this could point toward a more effective first-line treatment for advanced biliary tract cancer by making standard therapies work better.
What could go wrong: This is a very early Phase 1 trial with only 48 people, focused on safety and dosing. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma gallbladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BILIARY TRACT CANCER METASTATIC BILIARY TRACT CARCINOMA

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.